

Advanced microbiological Technology
Innovative and unique association:
6 exclusive probiotic strains with prebiotic fibre scFOS (short-chain fructo-oligosaccharides) which are specifically needed to rebalance the whole intestinal flora.
$\checkmark$ SELECTED MICROBIC STRAINS, notified at the European Microbial Strain Data Network: PROBIOTIC ACTIVITY
$\checkmark$ BIFIDOBACTERIUM LACTIS BSOI, LACTOBACILLUS ACIDOPHILUS LAO2 AND LACTOBACILLUS PARACASEI LPOO: 3 exclusive and SPECIFIC strains for an effective intestinal colonization
$\checkmark$ EXCLUSIVE STRAIN OF LACTOBACILLUS SALIVARIUS LS03: for a better adhesion to the intestinal mucosa and a SYNERGISTIC action with the colonization of the DIFFERENT PARTS of the intestinal tract
$\checkmark$ EXCLUSIVE STRAINS OF LACTOBACILLUS RHAMNOSUS LR06 AND LACTOBACILLUS PLANTARUM LP02: useful to counteract the spread of coliform bacteria (ESCHERICHIA COLI), by producing bacteriocins
$\checkmark$ HIGH RESISTANCE OF THE STRAINS DURING DIGESTION
proFLORA ${ }^{\text {TM }}$ is recommended for children, pregnant and breast-feeding women as well as for the elderly. It is also recommended for those who are affected by food intolerance and allergy.
$\checkmark$ scFOS (SHORT-CHAIN FRUCTO-OLIGOSACCHARIDES), ACTING SYNERGISTICALLY WITH THE MICROBIAL STRAINS: PREBIOTIC ACTIVITY

HIGH MICROBIAL VITALITY due to the presence of selected scFOS (short-chain fructo-oligosaccharides)

HIGH CAPACITY TO RESTORE normal intestinal function
VERY EASY TO BE USED by a patient
STABILITY AND CONTROLLED SURVIVAL of the strains during production and storage, which guarantees the product effectiveness until the expiration date.


Lactobacillus rhamnosus - LR06-DSM 21981

## Proflora ${ }^{\text {w }}$

## Uses

PROFLORA ${ }^{\text {TM }}$ is capable of rebalancing an intestinal flora alteration due to: unbalanced dietary habits, antibiotic treatments, physical and mental stress, diarrhoea, abdominal bloating, digestive disorders, tympanites.

The use of PROFLORA ${ }^{\text {TM }}$ is especially recommended for those affected by recurrent infections due to Escherichia coli.

Moreover, it is odourless and flavourless.

## Directions

Take 1 sachet of PROFLORA ${ }^{\text {TM }}$ daily, preferably between meals: melt the product in half a glass of water at room temperature, mix carefully and take straight away.

## Warnings

Do not exceed the recommended daily dose. Food supplements should not be used as a substitute for a varied and balanced diet and a healthy lifestyle. Keep out of the reach of children less than 3 years of age.

## Ingredients

Bifiidoabcetrium lactis BS 01 - LMG P- 21384, Lactobacillus acidophilus LA 02 - DSM 21717, Lactobacillus paracasei LPC00 - LGM P-21380, Lactobacillus rhamnosus LR06 - DSM 21981, Lactobacillus plantarum LP02 - LMG P-210120, Lactobacillus salivarius LS03 - DSM 22776, short-chain Fructo-oligosaccharides scFOS, Maltodextrin, Silicon Dioxide.

| SUPPLEMENT FACTS PER SACHET |  |
| :--- | :--- |
|  |  |
| Energetic value | $5.69 \mathrm{kcal}(23,82 \mathrm{~kJ})$ |
| Protein | 6.0 mg |
| Carbohydrate | $2,278.0 \mathrm{mg}$ |
| Fat | 0.2 mg |
|  |  |
| - Bifidobacterium lactis BSO1 | $\geq 1.00$ billion CFU* |
| - Lactobacillus acidophilus LA02 | $\geq 0.25$ billion CFU* |
| - Lactobacillus paracasei LPC00 | $\geq 0.25$ billion CFU* |
| - Lactobacillus rhamnosus LR06 | $\geq 0.25$ billion CFU* |
| - Lactobacillus plantarum LP02 | $\geq 0.25$ billion CFU* |
| - Lactobacillus salivarius LS03 | $\geq 0.02$ billion CFU* |
| short-chain fructo-oligosaccharides (scFOS) | 1500 mg |

The total amount of probiotic strains higher than 2 billion/sachet is guaranteed until the expiration date on the label, provided that the product is kept in an unopened package.

## Packaging

PROFLORA ${ }^{\text {TM }}$ is available in 10 or $30 \times 2.5 \mathrm{~g}$ sachets.

## Bibliography

1. Bottazzi V. - Il microbiota intestinale. Università degli Studi di Milano. Pubblicazione Mofin Alce, 2009.
2. Biffi E. - Studio sull'efficacia di EUBIOFLOR 1 e MICOX nle trattamento delle disbiosi. La Med. Biol., 2005/3; 3-18.
3. Faria A.M., Weiner H.L. - Oral tolerance: mechanisms and therapeutic applications. Clin Dev Immunol. 2006 Jun-Dec;13(2-4):143-57.
4. Guarner F., Malagelada J.R. - Gut flora in health and disease. Lancet. 2003 Feb 8;361(9356):512-9.
5. Heine H. - Medicina omotossicologica e regolazione di base: reazione immunologica di soccorso. La Med. Biol. 1998/4; 9-12.
6. Neutra M.R. - Current concepts in mucosal immunity. V Role of $M$ cells in transepithelial transport of antigens and pathogens to the mucosal immune system. Am J Physiol. Am J Physiol. 1998 May;274(5 Pt l):G785-91.
7. Perger F. - Ursachen un d Folgen von Dysbiosen des Darmtraktes. Arztezeithschr. Naturheilk 1, 36: 1991.
8. Perger F. - Regulations storungen und Darmkeimverhaltnisse. Thermodiagnostik 1, 1985.
9. Perugini F. Il sistema immunitario associato alle mucose (MALT) e la Medicina Biologica. La Med. Biol. 1996/4; 27-31.
10. Pilette C., Quadrhiri Y. et AI. - Lung mucosal immunity: immunoglobulin-A revisited. Eur Respir J. 2001 Sep;18(3):571-88.
11. Shanahan F. - The host-microbe interface within the gut. Best Pract Res Clin Gastroenterol. 2002 Dec;16(6):915-31.
12. Strober W. et AI. - Oral tolerance. J Clin Immunol. 1998 Jan;18(1):1-30.
